January AI’s Post

New publication in Diabetes Research and Clinical Practice provides a better understanding of the correlation between #MASLD and #T2D and a comprehensive review of the distinct role and effect of selective, dual and pan- PPARs, including lanifibranor.   Read the full article here: https://lnkd.in/ei6zbMKz Michael Cooreman, Luisa Vonghia, Sven Francque #MASLD #PPAR #T2D $IVA

Data is powerful and has a story to tell.. Inovalon can help give your data a voice.

The wait is finally over, we are thrilled to introduce our minimally-invasive Water Vapor Therapy, a cutting-edge treatment that has been successful in the USA, Europe, and other Asia Pacific countries.  Ready to empower your prostate care journey?  Explore our minimally invasive therapies today!Visit https://lnkd.in/g_Wkebvq know more. #ProstateCare #WaterVaporTherapy Maneesh Rajkumar Pherwani Shikha Mirchandani Chatrath Jatin Kakkar Harshh Makkar Arun Kumar, CSCP Animesh Thakur Sankalp Bajpai Madan R Krishnan Annie Sachdeva LIPIKA ARORA Manjushree Raina Payal Chaudhary Samrat Sarkar Charudatta Aradhye Shivani Kaul Bhavya Shrivastava Yuvraj DhingraDisclaimer: The information presented by Boston Scientific India is for educational purposes only and does not recommend self-management of health issues. The information should not be treated as comprehensive and does not intend to provide diagnosis, treatment or any medical advice. Individual results may vary, and hence, it is advisable to consult your doctor regarding any medical or health-related diagnosis or treatment options.

GLP-1 agonists, like Ozempic, aren't just transforming diabetes care – they’re sparking a revolution in off-label use. Leveraging Inovalon's real-world data, the industry's largest primary source patient dataset and advanced analytics, our team revealed insights into off-label use and prescribing trends of semaglutide. Key findings: • 1,850% surge in semaglutide use between 2018 and 2022 • Off-label users appear to be younger, predominantly female, and more likely to have obesity • Primary care physicians were the leading prescribers, with specialists frequently prescribing for commercial enrollees Discover how this robust data can help shape the future of healthcare: https://ow.ly/shNa50SKcYR #RealWorldData

🔊 Tomorrow! Join us to explore the nuances of #anticoagulation therapy in the US. Learn more & register > https://bit.ly/45gYr73 The discussion will focus on the findings of our scoping review in JTT that delves into the differences in the quality of care across ethnoracial groups, as well as valuable insights into how these disparities impact patient outcomes. Our expert panel: Andrea Van Beek, DNP, APRN, AGPCNP-BC, CACP (Moderator) Darren Triller, PharmD (Moderator) Sara Vazquez, PharmD, BCPS, CACP (Presenter) Naomi Yates, PharmD, BCACP (Panelist) Craig Beavers, PharmD, FACC, FAHA,FCCP,BCCP,CACP (Panelist)

Here’s a throwback to January 1922, a landmark time in medical history, when #insulin made its grand debut being used for the first time to treat a person with diabetes – transforming diabetes therapy forever 🍬 Fast forward to today and the #innovation torch is still burning bright. But now scientists have easy access to reagents like our anti-IGF1 #antibody – a useful tool in modern research that can help unlock deeper insights into insulin-like growth factors and their role in health and disease. From past milestones to present breakthroughs, the journey of #medical #science is nothing short of incredible! See how you can use anti-IGF in your #research: https://lnkd.in/eQ_DGfkw #diabetes #diabetesawareness

Live from #ADA2024 in Orlando! Our EVP & President, Que Thanh Dallara, Senior Director of Medical Affairs, Dr. Jennifer McVean, and U.S. Senior Sales Director, Nihal Singh, are inviting you to visit us at booth #1109 at the American Diabetes Association's 84th Scientific Sessions. What are you most excited to see from us this weekend? #MedtronicDiabetes #RethinkingDiabetesCare #MiniMed780G MiniMed™ 780G system is for type 1 ages 7 and over. Prescription required. WARNING: Do not use SmartGuard™ feature for people who require less than 8 units or more than 250 units of insulin/day. For details, see https://bit.ly/780gRisks

Hey! Welcome back from your long weekend! The ADA Scientific Sessions conference is on my mind this week and if you work in diabetes and/or obesity, I'm sure it is on your brain too. Our team at Thrivable will be there and I'd love to chat with anyone looking to improve their qualitative, quantitative, human factors and clinical trials. Comment below if you'd like to meet or send me a PM! #ADA2024

Physical therapy and Chiropractic care share a similar need in getting patients better faster. Power Plate helps clinics make this happen with less effort from clinicians. How? Our vibration technology achieves quick results through multiple physiological mechanisms: 💪Enhanced Muscle Activation: harmonic vibrations recruit more muscle fibers, improving strength, coordination, and functional output. 🧘Improved ROM: Oscillations optimize muscle and joint flexibility, promoting pain-free movement and preventing future injury. 😀Reduced Pain Sensitivity: Neurological modulation alters pain perception, providing immediate relief and enhancing treatment compliance. For clinics our advantages are shorter treatment sessions, quicker therapy gains, and motivated patients create a practice known for excellence and innovation. Boost your clinic's referral potential at https://lnkd.in/eXfv7HRM. #powerplate #Healthcare #Exercise #medicine #technology #innovation #physicaltherapy #chiropractic

Truveta Research's latest insights comparing weight loss trends for overweight/obese patients on #Mounjaro vs. #Ozempic was featured on NBC News's TODAY Show this week. Watch the segment, and learn more about the first-of-its-kind research here: https://tr.vet/3SXCUvY #MedicalData #WeightLoss #WeightLossDrugs #Diabetes #DiabetesDrugs #MedicalTechnology #MedTech #HealthData #HealthResearch #MedicalResearch #ComparativeEffectiveness